{"id":"W2252811454","doi":"10.1097/qai.0000000000000790","title":"Brief Report","year":2015,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":219,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network","funders":"Cilag; GlaxoSmithKline; ViiV Healthcare; Gilead Sciences; Pfizer; Bristol-Myers Squibb","keywords":"Dolutegravir; Abacavir; Lamivudine; Emtricitabine; Efavirenz; Medicine; Virology; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy; Chronic hepatitis; Virus","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.003097389,0.0009184413,0.0008589746,0.001387352,0.00190275,0.003765437,0.00189768,0.003508731,0.5358912],"category_scores_gemma":[0.01149149,0.0004089579,0.0008879098,0.0009154202,0.0005684315,0.00192305,0.002414998,0.002727603,0.3324662],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001481228,"about_ca_system_score_gemma":0.00549006,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002128963,"about_ca_topic_score_gemma":0.002504337,"domain_scores_codex":[0.9977109,0.0005622556,0.0002253932,0.000419736,0.0007903919,0.000291166],"domain_scores_gemma":[0.9933134,0.000868284,0.000366789,0.0009960313,0.002706472,0.001749087],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002833762,0.0001689525,0.001074196,0.0003256611,0.00002080673,0.0003644589,0.00007694971,0.00003276875,0.0002896686,0.00391514,0.8239903,0.1694577],"study_design_scores_gemma":[0.00006326067,0.00009882302,0.0007357646,0.0001875963,0.00001240803,0.0006672349,0.00007555499,0.00002374955,0.0001536455,0.001388518,0.9965845,0.000008907832],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"other","genre_gemma":"other","genre_scores_codex":[0.005528856,0.02253874,0.005396092,0.07759485,0.08524779,0.002063769,0.02035238,0.001752564,0.7795249],"genre_scores_gemma":[0.02463419,0.01389464,0.00395881,0.03667843,0.01677368,0.001262168,0.01427687,0.000519091,0.8880021],"genre_candidate":"other","genre_consensus":"other","teacher_disagreement_score":0.4641088,"threshold_uncertainty_score":0.6619948,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0341467119659951,"score_gpt":0.2919896861536674,"score_spread":0.2578429741876723,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}